Difference between revisions of "Gatifloxacin"

(Adverse Reactions)
 
(9 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
==General==
 
==General==
*Type:  
+
*Type: [[Fluoroquinolone]]
*Dosage Forms: Solution
+
*Dosage Forms: Ophthalmic solution
 
*Common Trade Names: Zymar, Zymaxid
 
*Common Trade Names: Zymar, Zymaxid
  
 
==Adult Dosing==
 
==Adult Dosing==
* 0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-qid x 6 days
+
*0.3% solution, 1 gtt in eye q2h up to 8x/day day 1 and 2, then QID x 5 days
 +
*0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-QID x 6 days
  
 
==Pediatric Dosing==
 
==Pediatric Dosing==
*> 1 y/o: 0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-qid x 6 days
+
*> 1 y/o
 +
**0.3% solution, 1 gtt in eye q2h up to 8x/day day 1 and 2, then QID x 5 days
 +
**0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-QID x 6 days
  
 
==Special Populations==
 
==Special Populations==
Line 42: Line 45:
  
 
==Pharmacology==
 
==Pharmacology==
*Half-life:  
+
*Half-life: N/A (7-14 hours for systemic preparations)
*Metabolism:  
+
*Metabolism: Minimal
*Excretion:  
+
*Excretion: N/A (urine for systemic preparations)
*Mechanism of Action:
+
*Mechanism of Action: Bactericidal, inhibits DNA gyrase and topoisomerase IV
  
 
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==
 
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==
Line 168: Line 171:
 
===Key===
 
===Key===
 
{{Template:Antibacterial Spectra Key}}
 
{{Template:Antibacterial Spectra Key}}
 +
 
==See Also==
 
==See Also==
  
==Source==
+
==References==
 
 
 
<references/>
 
<references/>
[[Category:Drugs]]
+
[[Category:Pharmacology]]
 +
[[Category:ID]]

Latest revision as of 20:08, 22 September 2019

General

  • Type: Fluoroquinolone
  • Dosage Forms: Ophthalmic solution
  • Common Trade Names: Zymar, Zymaxid

Adult Dosing

  • 0.3% solution, 1 gtt in eye q2h up to 8x/day day 1 and 2, then QID x 5 days
  • 0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-QID x 6 days

Pediatric Dosing

  • > 1 y/o
    • 0.3% solution, 1 gtt in eye q2h up to 8x/day day 1 and 2, then QID x 5 days
    • 0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-QID x 6 days

Special Populations

  • Pregnancy Rating: C
  • Lactation: Safety Unknown
  • Renal Dosing
    • Adult
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Conjunctival hemorrhage
  • Superinfection

Hypersensitivity reaction

Common

  • Conjunctival irritation
  • Ocular irritation
  • Dysgeusia
  • Ocular pain
  • Chemosis
  • Dry eyes
  • Ocular discharge
  • Blepharitis
  • Headache
  • Visual acuity changes

Pharmacology

  • Half-life: N/A (7-14 hours for systemic preparations)
  • Metabolism: Minimal
  • Excretion: N/A (urine for systemic preparations)
  • Mechanism of Action: Bactericidal, inhibits DNA gyrase and topoisomerase IV

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep S
Strep. anginosus gp S
Enterococcus faecalis S
Enterococcus faecium I
MSSA S
MRSA I
CA-MRSA I
Staph. Epidermidis S
C. jeikeium X1
L. monocytogenes S
Gram Negatives N. gonorrhoeae I
N. meningitidis S
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ S
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg S
Enterobacter sp, AmpC pos S
Serratia sp S
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris S
Providencia sp. S
Morganella sp. S
Citrobacter freundii S
Citrobacter diversus S
Citrobacter sp. S
Aeromonas sp S
Acinetobacter sp. I
Pseudomonas aeruginosa I
Burkholderia cepacia R
Stenotrophomonas maltophilia I
Yersinia enterocolitica S
Francisella tularensis X1
Brucella sp. X1
Legionella sp. S
Pasteurella multocida S
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp S
Mycoplasm pneumoniae S
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces S
Bacteroides fragilis I
Prevotella melaninogenica S
Clostridium difficile R
Clostridium (not difficile) S
Fusobacterium necrophorum X1
Peptostreptococcus sp. S

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. Sanford Guide to Antimicrobial Therapy 2014